Human Anti-APP Recombinant Antibody (clone hu5E3) (CAT#: HPAB-0105-YJ)

Figure 1 A qualitative assessment of the interactions between murine 5E3, cdr5E3, hu5E3 and rehu5E3 constructs and the cSNK:BSA conjugate using biolayer inter ferometry.

Key to the sensor traces: A4, D4, and E4: three clonal isolates of murine 5E3; B4: Empty; C4: Irrelevant Ab; F4: cdr5E3 (IgG1); G4: hu5E3 (IgG1); and H4: rehu5E3 (IgG1).

Figure 2 A graph showing the immunoreactivity of murine 5E3, chimeric 5E3 IgG1, and humanized 5E3 IgG1 constructs (hu5E3, rehu5E3, and cdr5E3) to captured cSNK by ELISA.

Figure 3 The results of Western immunoblots with murine and humanized 5E3 constructs purified from CHOK1SV cells.

Blots were probed with either murine 5E3 (m5E3), or humanized 5E3 IgG1, IgG2 and IgG4 mAbs against the cSNK epitope conjugated to BSA (BSA-cSNK). These blots were only positive for the cSNK epitope and did not bind the negative controls (unconjugated BSA or Ovalbumin).

Figure 4 Western immunoblot analysis of non-reduced 5 ug of BSA, cSNK conjugated to BSA (BSA-cSNK) and ovalbumin control (OVA) probed with purified hu5E3 IgG1.

Figure 5 Western immunoblot analysis of non-reduced purified hu5E3 IgG1 probed with anti-human IgG.

Figure 6 Binding of hu5E3 IgG1, IgG2, and IgG4 isotypes to Amyloid beta oligomers (Αβ oligomers) prepared from recombinant Αβ peptides by biacore.

Figure 7 Binding of hu5E3-IgG1 to Amyloid beta oligomers (Αβ oligomers) prepared from recombinant Αβ peptides by biacore.

Figure 8 The immunoreactivity of humanized 5E3 IgG1 and Δ5Ε3 IgG1 constructs to captured cSNK by ELISA.

Figure 9 The immunoreactivity of humanized 5E3 IgG1 and Δ5Ε3 IgG1 constructs to captured ccSNK by ELISA.